Epoetin-α during radiotherapy for stage III esophageal carcinoma: A prospective, nonrandomized study

Cancer

Volumn 103, Issue 11, 2005, Pages 2274-2279

  Rades, Dirk ^a   Schild, Steven E ^b   Yekebas, Emre F ^a   Job, Hendric ^a   Schwarz, Rudolf ^a   Rudat, Volker ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

Epoetin ; Esophageal carcinoma; Radiotherapy; Tumor oxygenation

Indexed keywords

FLUOROURACIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LYMPH NODE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR CLASSIFICATION;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; ESOPHAGEAL NEOPLASMS; FEMALE; GAMMA RAYS; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 18844379370     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21042     Document Type: Article

References (24)

1. Vaupel P, Thews O, Hockel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2001;18:243-259.
2. Harrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy, prognostic significance and treatment. Oncology. 2002;63(Suppl 2):11-18.
3. Vaupel P, Thews O, Mayer A, et al. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol. 2002;178:727-731.
4. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 2001;50:705-715.
5. Blohmer JU, Wurschmidt F, Petry U, et al. Sixth interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: sequential adjuvant chemo-radiotherapy with versus without Epoetin alfa for patients with high-risk cervical cancer [abstract]. Proc Am Soc Clin Oncol 2003;22:447.
6. Antonadou D, Cardamakis E, Sarris G, Tzigounis V, Throuvalas N. Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy [abstract]. Radiother Oncol. 1998;48(Suppl 1):S122.
7. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
8. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
9. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96:823-833.
10. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys. 1993;27:1147-1152.
11. Dusenbery KE, McGuie WA, Holt PJ, et al. Erythropoietin increases hemoglobin during radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 1994;29:1079-1080.
12. Sweeney PJ, Nicolae D, Ignacio L, et al. Effect of subcutaneous recombinant erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labeled Phase II trial. Br J Cancer. 1998;77:1996-2002.
13. Becker A, Stadler P, Lavay RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2000;46:459-466.
14. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528-1536.
15. Munstedt K, Volzing M, Von Georgi R. Hemoglobin levels during radiotherapy and their influence on local control and survival of patients with endometrial carcinoma. Oncol Rep. 2004;11:711-717.
16. Rabeneck L, Viscoli CM, Horwitz RI. Problems in the conduct and analysis of randomized clinical trials: are we getting the right answers to the wrong questions? Arch Intern Med. 1992;152:507-512.
17. Concato J, Shah N, Horwitz RI. Randomized controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.
18. Westphal G, Niederberger L, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 2002;88:150-159.
19. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000;58:647-657.
20. Selzer E, Wachek V, Kodym R, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res. 2000;179:527-534.
21. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003;162:1789-1806.
22. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest. 2003;83:1477-1487.
23. Stuben G, Thews O, Pottgen C, et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol. 2001;127:346-350.
24. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res. 2001;61:1358-1361.